About LUNAC Therapeutics
At LUNAC Therapeutics we're developing a first-in-class, next generation oral anticoagulant for the treatment and prevention of life-threatening thrombotic events, without the bleeding risk associated with current anticoagulants.
Our focus is on the inhibition of activated Factor XII (FXIIa), a clotting factor enzyme which plays a key role in pathological clot formation (thrombosis) but not in the stemming of bleeding (haemostasis).
LUNAC is a spin-out company from the University of Leeds, founded and supported by world-leading experts in blood coagulation.
Oral anticoagulants are life-saving drugs which are significantly under-utilised because of the difficulty of balancing anti-thrombotic activity with risk of major bleeding. All current anticoagulants target parts of the coagulation cascade which are essential for normal blood clotting.
LUNAC Therapeutics is taking a different approach; our first-in-class oral small molecule targets activated Factor XII (FXIIa), a coagulation factor enzyme that plays a key role in pathological occlusive clot formation but not in the normal stemming of bleeding.
CONSULTANTS & ADVISORS
Please complete the form below...